Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multicenter Clinical Study of High-dose Furmonertinib in First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

NCT05379803 is registered in ClinicalTrials.gov with Hunan Province Tumor Hospital as lead sponsor.

NCT NCT05379803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05379803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multicenter Clinical Study of High-dose Furmonertinib in First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Lead sponsor
Hunan Province Tumor Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2022
Completion date
March 31, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer